ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2239

Validation Of a Patient Reported Experience Measure In Patients With Rheumatoid Arthritis

Marwan Bukhari1, Peter Jones2, Ifeanyi Sargeant3, Maureen Cox4, Alison Elliott5, Suzanne Bullock6, Anne O'Brien2 and Ailsa Bosworth7, 1Department of Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom, 2Keele University, Keele, United Kingdom, 3IS medical communications, Stafford, United Kingdom, 4Nuffield Orthopaedic centre, Oxford, United Kingdom, 5Roche Pharmaceuticals, Welwyn Garden City, United Kingdom, 6Lancaster University, Lancaster, United Kingdom, 7National Rheumatoid Arthritis Society, Maidenhead, United Kingdom

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: outcome measures and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis-Clinical Aspects III: Outcome Measures, Socioeconomy, Screening, Biomarkers in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose:   Improving patient experience is important in all diseases, but most important in patients with chronic rheumatic diseases like rheumatoid arthritis. To date there have been no specific patient reported experience measures (PREMs) in rheumatology.  A multi-disciplinary group ¸commisioning for quality in rheumatoid arthritis (CQRA) was established to develop the first PREM in RA, this  group was supported under the terms of a joint working agreement with Roche Products Ltd. Firstly, a series of focus groups was held with patients from the UK National Rheumatoid Arthritis  Society to determine which elements of the patient experience was deemed most important and this was mapped against  UK Department of Health Patient Experience Framework. This framework comprises 8 domains. A questionnaire was developed using the same 8 domains, but with questions developed specifically relating to RA and Rheumatology Services and these were piloted across ten UK sites. The final question asked  respondents to evaluate their overall level of care. All questions were graded from very satisfied to very unsatisfied on a five point scale.

Aim: To determine the construct validity of the PREM questionnaire developed by the CQRA group.

Methods: Cronbachs alpha was used to check internal consistency within groups of scores in each domain if it contained more than one question  and whether it was reasonable to combine scores within groups into a numerical scale.  Additionally for each question the percentage agreement with the overall assessment on the five point scale was calculated, in case of multiple questions per domain, the responses are shown as a range.

Results:

524 patients were included in the analysis, median age was 65 years (IQR 55,80 years).  377 (72%) were female. Median disease duration was 8 years (IQR 3.5, 15 years).  The Cronbach alpha co-efficients within the multi-question domains and their percentage agreement with the question on overall care are shown in table1 below.

Domain

Number of questions

Alpha within domain

%Agreement with overall care

Needs and preferences

5

0.90

64.5-67.2

Co-ordination of care

4

0.87

59.1-69.1

Information about care

4

0.75

22.5-66.4

Daily living

2

0.61

33.2-53.4

Emotional support

2

0.84

53.5-68.9

Family and friends

1

–

61.8

Access to care

1

–

70.4

Table 1. Result of Cronbach’s alpha analysis and their agreement with overall care

Conclusion: The PREM has good construct validity and is a valid tool for measuring RA patient experience. Some domains have higher agreement with overall patient experience. This could provide a useful future tool for measuring patient experience. Modification of the tool to use in other rheumatic conditions is underway.


Disclosure:

M. Bukhari,
None;

P. Jones,
None;

I. Sargeant,
None;

M. Cox,
None;

A. Elliott,
None;

S. Bullock,
None;

A. O’Brien,
None;

A. Bosworth,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-a-patient-reported-experience-measure-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology